CFDA: 80% Of China’s Drug Applications Rely On Faulty Data

According to a shocking CFDA investigation, 80% of the applications for new drugs in China rely on compromised data. The results contained fabricated or fraudulent numbers, omitted adverse events, offered incomplete or missing source documents, or other infractions. The CFDA closely examined the clinical data from 1,622 new drug applications to arrive at the 80% failure rate. In the case of generic drugs, data was simply made up to prove bioequivalence in 90% of the cases. Because so many drugs failed scrutiny, the efficacy of China’s entire drug supply is now questionable.